Compare NBIX & UNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBIX | UNM |
|---|---|---|
| Founded | 1992 | 1848 |
| Country | United States | United States |
| Employees | N/A | 10910 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Accident &Health Insurance |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.5B | 15.1B |
| IPO Year | 1996 | 1995 |
| Metric | NBIX | UNM |
|---|---|---|
| Price | $144.27 | $93.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 11 |
| Target Price | ★ $180.91 | $83.36 |
| AVG Volume (30 Days) | 927.8K | ★ 1.6M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 2.26% |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 3.30 | 3.01 |
| Revenue | $161,626,000.00 | ★ $13,075,500,000.00 |
| Revenue This Year | $24.73 | N/A |
| Revenue Next Year | $13.14 | $4.98 |
| P/E Ratio | $44.30 | ★ $31.77 |
| Revenue Growth | ★ 977.51 | 1.46 |
| 52 Week Low | $122.14 | $69.02 |
| 52 Week High | $186.12 | $96.77 |
| Indicator | NBIX | UNM |
|---|---|---|
| Relative Strength Index (RSI) | 30.58 | 55.04 |
| Support Level | $141.00 | $86.51 |
| Resistance Level | $161.41 | $94.55 |
| Average True Range (ATR) | 4.33 | 2.07 |
| MACD | -0.74 | -0.02 |
| Stochastic Oscillator | 1.21 | 57.23 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Unum Group is a provider of group and individual income protection insurance products in the United States, the United Kingdom, Poland, and other countries. It is the domestic disability insurer, with the majority of premiums generated from employer plans. The company also offers a complementary portfolio of other insurance products, including long-term care insurance, life insurance, and employer- and employee-paid group benefits. It has the following operating business segments: Unum USA, Unum International, Closed Block, Colonial Life, and Corporate. The Unum USA segment generates the majority of revenue. The firm markets its products through brokers.